Antihypertensive Drug Box Sales Between January 2019 - June 2024 in Turkish Drug Market: Investigating the Drug Group and Fix-Dose Combination Sales

Authors : Elif Hilal Vural, Bülent Gümüşel

Pages : 65-78

Doi:10.55262/fabadeczacilik.1583943

View : 20 | Download : 14

Publication Date : 2025-03-25

Article Type : Research Paper

Abstract :Financial and emotional burden of chronic diseases including hypertension have been rising. In this study we aimed to evaluate the box sales trends of antihypertensive drugs in Türkiye and to compare these trends among the drug groups. This study analyzed retail and hospital box sales of antihypertensive drug groups recommended by guidelines between January 2019 and June 2024. The data used in this study were obtained from IQVIA. While antihypertensive drugs sold a total of 176,453,254 boxes in 2019, it was increased by 15.44% and sold 203,690,099 boxes in 2023. The best-selling drug group is the Renin-Angiotensin System (RAS) antagonists. Angiotensin Receptor Blocker-Diuretic fixed-dose combination (FDC) is the best- selling subgroup in the RAS antagonists. FDCs of RAS antagonists are more often used than their mono forms, and in 2022 and 2023 FDC of calcium channel blockers have begun to outsell their combined formulations. Triple FDCs of the RAS antagonists with calcium channel blockers and diuretics have been increasing regularly. In Türkiye drug groups that have the highest share in the antihypertensive drug market in recent years are the groups recommended in the guidelines. Increasing in triple FDC sales is valuable in terms of evaluating the rational treatment of hypertension.
Keywords : antihipertansif ilaçlar, akılcı ilaç kullanımı, kutu satışları, sabit doz ilaç kombinasyonu